A Case of Seronegative Myopathy-Myocardial Injury Due to PD-1 Inhibitor and Literature Review

免疫检查点抑制剂(ICI)相关性疾病是肿瘤免疫治疗的重要并发症，其中PD-1抑制剂可通过阻断PD-1/PD-L1信号通路引发多系统免疫损伤。此类疾病临床表现异质性高，肌病–心肌损伤重叠综合征尤为罕见且预后差。本文报告一例以抗体阴性的PD-1抑制剂(替雷利珠单抗)相关重症肌无力样肌病–心肌损伤重叠综合征并做文献复习，为临床上诊断和治疗该疾病提供参考。Immune checkpoint inhibitor (ICI)-associated diseases are important complications of tumor immunotherapy, in which PD-1 inhibitors can trigger multisystemic immune injury by blocking the PD-1/PD-L1 signaling pathway. The clinical manifestations of these diseases are highly heterogeneous, and myopathy-myocardial injury overlap syndrome is particularly rare and has a poor prognosis. In this article, we report a case of myasthenia gravis-like myopathy-myocardial injury overlap syndrome associated with an antibody-negative PD-1 inhibitor (tirilizumab) and review the literature to provide a reference for the diagnosis and treatment of this disease in clinical practice.